| Wearing-off 현상을 경험하는 파킨슨병 환자에서 엔타카폰의 효과 및 안정성: 다기관 무작위 위약비교 이중맹검 연구 |
| 임주혁, 이준균 정선주 전범석* 조진환* 이명식† 조은경† 이원용‡ 이은아‡
김재우§ 이명종 |
| 울산대학교 의과대학 서울아산병원 신경과, 서울대학교 의과대학 신경과학교실*,
연세대학교 의과대학 영동세브란스병원 신경과†, 성균관대학교 의과대학 삼성서울병원 신경과‡,
동아대학교 의과대학 신경과학교실§ |
| Efficacy and Safety of Entacapone in the Patients with Parkinson’s Disease Experiencing Wearing-off Phenomenon: Multicenter Randomized Placebo-controlled Double Blind Study |
| Joo-Hyuk Im |
| Department of Neurology, University of Ulsan College of Medicince, Asan Medical Center, Seoul;
Department of Neurology, Seoul National University College of Medicine*, Seoul;
Department of Neurology, Yonsei University College of Medicine†, Yongdong Severance Hospital, Seoul;
Department of Neurology, Sungkyunkwan University School of Medicine‡, Samsung Medical Center, Seoul;
Department of Neurology, Dong-A University College of Medicine§, Busan, Korea |
|
|
|
|
| Abstract |
Background: The purpose of this study was to assess the efficacy and safety of entacapone, a catechol-O- methyltransferase (COMT) inhibitor in Parkinson's disease (PD) patients with wearing-off phenomenon.
Methods: A total of 197 PD patients were included in this 2-month multi-center, randomized, placebo-controlled, double blind, parallel-group study. After a 2-week screening period, each patient was randomly allocated to receive either entacapone (n=98) or placebo (n=99) as an adjunct to levodopa. The efficacy was evaluated with the changes of “on” and “off” time percentage while awake, the reduction of the levodopa dose, Unified Parkinson's Disease Rating Scale (UPDRS), and the clinical global impression (CGI) by the examiner.
Results: The percentage of “on” time increased by 9.4±18.0% in the entacapone group, 7.4±15.6% in the placebo group. The percentage of “off” time was reduced by 8.6±16.9% in the entacapone group, 6.6±18.2% in the placebo group. These parameters did not show a statistical significance between the two groups. However, the levodopa dose was significantly reduced in the entacapone group (51.6±154.5 mg/day) compared with the placebo group (0.7±130.0 mg/day) (p=0.009). The total and motor scores of the UPDRS were significantly decreased in the entacapone group (p=0.039, p=0.017, respectively). The most common adverse drug reactions in the entacapone group were urine discoloration (22%), dyskinesia (13%), dizziness (7%).
Conclusions: Entacapone was a safe and well-tolerated drug. Although the changes of “on” and “off” time were not significant, entacapone showed an overall significant beneficial effect in the PD patients with wearing-off phenomenon.KeyWords:Parkinson's disease, Entacapone, Wearing-off phenomenon, Motor fluctuation |
|
PDF Links
Full text via DOI
Download Citation
